Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
AnGes Jettisons Ancestral COVID-19 Vaccine Program
AnGes said on September 7 that it will terminate the development of its COVID-19 DNA vaccine candidate based on the ancestral strain of the novel coronavirus, including high-dose versions, after clinical trials failed to deliver expected results. The Osaka University…
To read the full story
Related Article
- Govt Laments AnGes’ Aborted COVID Vaccine Project, Renews Pledge to Back Potential Seeds
September 12, 2022
- AnGes COVID-19 Vaccine Falls Short in Clinical Trials, Focus Now on High Doses
November 8, 2021
- 5 Companies Developing Japan-Made COVID-19 Jabs Face Challenges in Subject Enrollment, Trial Designs
September 29, 2021
- AnGes Launches PI/II Study for High-Dose COVID-19 Vaccine
August 18, 2021
- AnGes Adds High-Dose Trial to COVID-19 Vaccine Program
July 27, 2021
- Dosing of Low-Dose COVID-19 Vaccine Completed: AnGes PI/II Study
July 27, 2020
- AnGes’ COVID-19 Vaccine Given Some Safety Confirmation Before Clinical Trial: MHLW Official
July 9, 2020
- AnGes Launches Clinical Trial for Coronavirus DNA Vaccine
July 1, 2020
- AnGes/Osaka Univ. Plan Small COVID-19 Vaccine Study from July, Larger One from September
June 5, 2020
- Keio Univ. Spinout Weighs In on AnGes' COVID-19 Vaccine Initiatives
April 28, 2020
- Shin Nippon Biomedical Joins AnGes Vaccine Development
April 22, 2020
- Osaka Pref., Osaka Univ. Form Alliance for COVID-19 Vaccine; AnGes Clinical Study Planned as Early as July
April 16, 2020
- Peptide Institute Latest to Chip In with AnGes to Develop Novel Coronavirus Vaccine
April 15, 2020
- FunPep Joins AnGes, Osaka Univ. Partnership to Develop Novel Coronavirus Vaccine
April 9, 2020
- AnGes Now Ready to Launch Preclinical Study for Coronavirus DNA Vaccine
March 25, 2020
- Daicel, AnGes/Osaka Univ. to Collaborate in Developing COVID-19 Vaccine
March 16, 2020
- AnGes, Osaka Univ. to Pair Up to Develop DNA Vaccines for COVID-19
March 6, 2020
BUSINESS
- Chugai Forms Strategic Investment Unit to Deepen Innovation Push; Record Japan Filings Eyed
July 27, 2026
- Chugai Notches Strong H1 Growth on Key Products, Roche Exports
July 27, 2026
- Meiji’s Hiyasta Hits PIII Goal in Advanced Melanoma
July 27, 2026
- China First to Approve Takeda’s Oveporexton for Narcolepsy
July 24, 2026
- FRONTEO Expects First US User of KIBIT AI Engine This Year: CEO
July 24, 2026
Japan’s pharmaceutical industry could be on the verge of gaining a stronger voice in the Central Social Insurance Medical Council…
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…